Therapeutic alternatives for difficult-to-treat depression: A narrative review of the state of the evidence

被引:47
作者
Thase, ME
机构
[1] Univ Penn, Med Ctr, Dept Psychiat, Pittsburgh, PA 15213 USA
[2] Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA 15213 USA
关键词
D O I
10.1017/S1092852900002236
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Despite the large number of depressed patients who do not respond to first-line antidepressants, the evidence base of alternate strategies is quite thin. In this article, a simple 5-stage system for categorizing treatment-resistant depression (TRD) is described and the evidence pertaining to the major strategies currently utilized is summarized using four grades, ranging from D (case reports only) to A (multiple positive placebo-controlled trials). It is concluded that the level of evidence supporting many of the contemporary strategies used for TRD (eg, combinations of antidepressants and augmentation with medications such as pindolol, buspirone, or modafinil) is scanty at best. Even the fundamental question concerning "to augment or to switch" is not answerable with available data. It is noted that the best-documented treatments (ie, lithium augmentation, switching to a monoamine oxidase inhibitor, and electroconvulsive therapy) are among the least utilized. This state of affairs will improve with completion of the studies of Systematic Treatment Alternatives to Relieve Depression, a large multicenter study of difficult-to-treat depression funded by the National Institute of Mental Health. There is a need for greater collaboration among academicians and organizations, such as the American Psychiatric Association, the National Institute of Mental Health, and the pharmaceutical industry, to ensure that sufficient research is conducted so that clinician's choices for patients with TRD can be guided by empirical evidence.
引用
收藏
页码:808 / 821
页数:18
相关论文
共 125 条
[81]   Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment [J].
Perry, A ;
Tarrier, N ;
Morriss, R ;
McCarthy, E ;
Limb, K .
BRITISH MEDICAL JOURNAL, 1999, 318 (7177) :149-153
[82]   Venlafaxine and paroxetine in treatment-resistant depression - Double-blind, randomised comparison [J].
Poirier, MF ;
Boyer, P .
BRITISH JOURNAL OF PSYCHIATRY, 1999, 175 :12-16
[83]   The effectiveness of switching antidepressants during remission: a case series of depressed patients who experienced intolerable side effects [J].
Posternak, MA ;
Zimmerman, M .
JOURNAL OF AFFECTIVE DISORDERS, 2002, 69 (1-3) :237-240
[84]   Novel uses of thyroid hormones in patients with affective disorders [J].
Prange, AJ .
THYROID, 1996, 6 (05) :537-543
[85]   Comparison of unlimited numbers of rapid transcranial magnetic stimulation (rTMS) and ECT treatment sessions in major depressive episode [J].
Pridmore, S ;
Bruno, R ;
Turnier-Shea, Y ;
Reid, P ;
Rybak, M .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2000, 3 (02) :129-134
[86]   MEDICATION RESISTANCE AND CLINICAL-RESPONSE TO ELECTROCONVULSIVE-THERAPY [J].
PRUDIC, J ;
SACKEIM, HA ;
DEVANAND, DP .
PSYCHIATRY RESEARCH, 1990, 31 (03) :287-296
[87]  
Prudic J, 1996, AM J PSYCHIAT, V153, P985
[88]   When should a trial of fluoxetine for major depression be declared failed? [J].
Quitkin, FM ;
Petkova, E ;
McGrath, PJ ;
Taylor, B ;
Beasley, C ;
Stewart, J ;
Amsterdam, J ;
Fava, M ;
Rosenbaum, J ;
Reimherr, F ;
Fawcett, J ;
Chen, Y ;
Klein, D .
AMERICAN JOURNAL OF PSYCHIATRY, 2003, 160 (04) :734-740
[89]  
Rosenbaum JF, 2001, TREATMENT PSYCHIATRI, P1307
[90]   Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder [J].
Rush, AJ ;
Armitage, R ;
Gillin, JC ;
Yonkers, KA ;
Winokur, A ;
Moldofsky, H ;
Vogel, GW ;
Kaplita, SB ;
Fleming, JB ;
Montplaisir, J ;
Erman, MK ;
Albala, BJ ;
McQuade, RD .
BIOLOGICAL PSYCHIATRY, 1998, 44 (01) :3-14